In addition, foreign studies (38, 39) conclude that MYC/BCL2 co-expression in DLBCL is associated with an aggressive clinical course, which is more common in the ABC subtype, and contributes to the overall inferior prognosis of patients with ABC-DLBCL. The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.